{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRI+chest%2C+abdomen+and+pelvis", "query": { "intervention": "MRI chest, abdomen and pelvis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 26, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MRI+chest%2C+abdomen+and+pelvis&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T21:44:58.439Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01862315", "title": "Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma", "Peripheral Cholangiocarcinoma", "Cholangiolar Carcinoma", "Cholangiocellular Carcinoma" ], "interventions": [ { "name": "Floxuridine (FUDR)", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "MRI", "type": "OTHER" }, { "name": "Research blood draws", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 56, "start_date": "2013-05", "completion_date": "2025-03-18", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01862315" }, { "nct_id": "NCT03952637", "title": "A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lysosomal Diseases", "Gangliosidosis", "GM1" ], "interventions": [ { "name": "AAV9-GLB1", "type": "BIOLOGICAL" }, { "name": "Abdominal ultrasound", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Audiology assessment with ABR", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone density scan (DEXA)", "type": "DIAGNOSTIC_TEST" }, { "name": "Electrocardiogram (EKG)", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Electroencephalogram (EEG) awake and extended overnight", "type": "OTHER" }, { "name": "Laboratory tests", "type": "DIAGNOSTIC_TEST" }, { "name": "Lumbar puncture", "type": "PROCEDURE" }, { "name": "Brain MRI/MRS/fMRI", "type": "PROCEDURE" }, { "name": "Neurocognitive testing", "type": "BEHAVIORAL" }, { "name": "Neurology exam", "type": "OTHER" }, { "name": "PICC or other Central line placement", "type": "BEHAVIORAL" }, { "name": "Skeletal survey", "type": "PROCEDURE" }, { "name": "Skin biopsy", "type": "PROCEDURE" }, { "name": "Speech and modified barium swallow study", "type": "PROCEDURE" }, { "name": "Ophthalmology exam", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "DIAGNOSTIC_TEST", "OTHER", "BEHAVIORAL" ], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Months to 12 Years" }, "enrollment_count": 54, "start_date": "2019-08-19", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952637" }, { "nct_id": "NCT03092518", "title": "Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Esophagogastric Junction", "Gastric Cancer" ], "interventions": [ { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Mitomycin C", "type": "DRUG" }, { "name": "Sodium Thiosulfate", "type": "DRUG" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" }, { "name": "CT C/A/P", "type": "DIAGNOSTIC_TEST" }, { "name": "PET-CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2017-06-05", "completion_date": "2024-07-24", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03092518" }, { "nct_id": "NCT05825066", "title": "Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreas Adenocarcinoma", "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiological Assessments", "type": "OTHER" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2023-08-01", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05825066" }, { "nct_id": "NCT03824275", "title": "18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "18F- DCFPyL PET/CT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 129, "start_date": "2019-02-12", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03824275" }, { "nct_id": "NCT04538378", "title": "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR-Mutated Non-Small-Cell Lung Carcinoma", "Small Cell/Neuroendocrine" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "CT chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-07-07", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04538378" }, { "nct_id": "NCT03315871", "title": "Combination Immunotherapy in Biochemically Recurrent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Antigen direct immunotherapy: PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "Antigen direct immunotherapy: PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "MSB0011359C (M7824)", "type": "DRUG" }, { "name": "Antigen direct immunotherapy: CV301", "type": "BIOLOGICAL" }, { "name": "CT scan of chest", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scan of abdomen/pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PSMA", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2018-03-20", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2025-06-19", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03315871" }, { "nct_id": "NCT02911142", "title": "Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Effusion Lymphoma", "B-Cell Neoplasm" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CT of neck, chest, abdomen and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "18FDG-PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone marrow biopsy", "type": "PROCEDURE" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Ultrasound", "type": "DIAGNOSTIC_TEST" }, { "name": "Bronchoscopy", "type": "DIAGNOSTIC_TEST" }, { "name": "Endoscopy", "type": "DIAGNOSTIC_TEST" }, { "name": "CXR: PA/lat/decub", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-07-03", "completion_date": "2028-10-01", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02911142" }, { "nct_id": "NCT06942104", "title": "Imaging of Solid Tumors Using 18F-TRX", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Solid Carcinoma", "Castration-Resistant Prostate Carcinoma", "Locally Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Glioma, Malignant" ], "interventions": [ { "name": "18F-TRX", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)/Computerized tomography (CT)", "type": "PROCEDURE" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" }, { "name": "Blood Specimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2025-07-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06942104" }, { "nct_id": "NCT06401330", "title": "A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Mixed Cell Type Kidney Wilms Tumor", "Stage II Mixed Cell Type Kidney Wilms Tumor", "Stage III Mixed Cell Type Kidney Wilms Tumor", "Stage IV Mixed Cell Type Kidney Wilms Tumor" ], "interventions": [ { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nephrectomy", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 1656, "start_date": "2025-04-15", "completion_date": "2031-02-13", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-05T21:44:58.439Z", "location_count": 154, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 129 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06401330" } ] }